bmp5 Search Results


94
MedChemExpress human bmp5 recombinant protein
GLDN regulates <t>BMP5/P-SMAD1/5/9</t> signaling in GLDN + OSCs. a uMAP representation of BMP5 . b IF co-staining of GLDN (green) and BMP5 (red) in sagittal sections of human developing DP tissues at an early root development stage (with root development not exceeding one-third of its final length), with DAPI (blue) indicating cell nuclei. Gel images ( c ) and grayscale value analysis of BMP5 ( d ) and P-SMAD1/5/9 ( e ) expression in GLDN-negative cells and GLDN + OSCs. n = 3. f ELISA analysis of BMP5 expression levels in CM from GLDN - DPSCs and GLDN + OSCs. n = 4. g – i Effects of GLDN silencing on BMP5 and P-SMAD1/5/9 expression in GLDN + OSCs. n = 3. j Expression of BMP5 in GLDN + OSCs-derived CM after GLDN silencing was assessed by ELISA. n = 4. k , l Effects of CM from GLDN + OSCs with GLDN silencing on P-SMAD1/5/9 expression in HUVEC cells. n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.000 1; ns no significance
Human Bmp5 Recombinant Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmp5/Animal-Free+BMP-5%2C+Human/pmc12948983-266-11-20
Average 94 stars, based on 1 article reviews
human bmp5 recombinant protein - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

93
Proteintech bmp5
G9a knockdown may lead to increase in <t>BMP5</t> expression. ( A ) Regulatory factors suppressing tumor aggressiveness were identified by using microarray analysis. ( B ) Expression levels for each gene were compared (ratios between gene expression levels of non-silencing control). In two G9a knockdown cells (shG9a #1 and shG9a #2), expression levels for each gene were compared to those of non-silencing control. Then the most upregulated and downregulated genes were screened. ( C ) G9a knockdown cells showed increase in BMP5 expression. ( D ) Reduced G9a occupancy was found at the BMP5 promoter region. G9a knockdown cells also showed decreased H3K9me2 occupancy at the promoter region of BMP5. p values were calculated using ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Bmp5, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmp5/BMP5+Antibody/pmc08776044-136-53-55
Average 93 stars, based on 1 article reviews
bmp5 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

90
R&D Systems bmp5
Fig. 9. Megalin mediates binding and cellular catabolism of BMP4. (A) Surface plasmon resonance (SPR) analysis of binding of 0.5 µmol/l BMP4 but not of 0.5 µmol/l <t>BMP5</t> or WNT1- conditioned medium to purified megalin immobilized on the sensor chip surface (see Materials and methods for details). As a positive control, binding of 1 µmol/l receptor-associated protein (RAP) to megalin was tested. (B) Megalin-expressing BN16 cells mediate uptake and lysosomal degradation of 125I-BMP4. Degradation of BMP4 can be blocked by chloroquine (200 µmol/l) or the receptor-antagonist RAP (100 µg/ml).
Bmp5, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmp5/Recombinant+Human+BMP-5+(CHO-expressed)+Protein%2C+CF/pm15623804-72-13-20
Average 90 stars, based on 1 article reviews
bmp5 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
R&D Systems antibodies against human bmp2 bmp4
Fig. 9. Megalin mediates binding and cellular catabolism of BMP4. (A) Surface plasmon resonance (SPR) analysis of binding of 0.5 µmol/l BMP4 but not of 0.5 µmol/l <t>BMP5</t> or WNT1- conditioned medium to purified megalin immobilized on the sensor chip surface (see Materials and methods for details). As a positive control, binding of 1 µmol/l receptor-associated protein (RAP) to megalin was tested. (B) Megalin-expressing BN16 cells mediate uptake and lysosomal degradation of 125I-BMP4. Degradation of BMP4 can be blocked by chloroquine (200 µmol/l) or the receptor-antagonist RAP (100 µg/ml).
Antibodies Against Human Bmp2 Bmp4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmp5/Mouse+BMP-5+Antibody/pmc06139562-419-0-21
Average 90 stars, based on 1 article reviews
antibodies against human bmp2 bmp4 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology anti bmp 5
Fig. 9. Megalin mediates binding and cellular catabolism of BMP4. (A) Surface plasmon resonance (SPR) analysis of binding of 0.5 µmol/l BMP4 but not of 0.5 µmol/l <t>BMP5</t> or WNT1- conditioned medium to purified megalin immobilized on the sensor chip surface (see Materials and methods for details). As a positive control, binding of 1 µmol/l receptor-associated protein (RAP) to megalin was tested. (B) Megalin-expressing BN16 cells mediate uptake and lysosomal degradation of 125I-BMP4. Degradation of BMP4 can be blocked by chloroquine (200 µmol/l) or the receptor-antagonist RAP (100 µg/ml).
Anti Bmp 5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmp5/BMP-5+Antibody/pm11036092-64-0-9
Average 93 stars, based on 1 article reviews
anti bmp 5 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

92
R&D Systems recombinant mouse bmp5
Fig. 2. Comparison of the Sox10, Mitf and Bmp expression patterns during the initial stages of chick eye development. (A) Schematic illustrating the location of the section in H, showing the nasal part of the optic vesicle at stage 10/11. (B) Bmp4 expression in the surface ectoderm overlying the optic vesicle following whole-mount in situ hybridisation (13 somites). The optic primordium is shown at stage 8 (6 somites; C,F,I,L,O), at stage 9 (7-9 somites; D,G,J,M,P) and stage 10 (10-12 somites; E,H,K,N,Q). (C) At stage 8, Sox10-positive neural crest cells are observed in the dorsal neural folds of the prosencephalon (arrows). (D) Sox10-expressing neural crest cells are detected in the dorsal-most region of the prosencephalon (arrows) and no transcripts are detected distally. (E) Sox10 expression is detected in neural crest cells overlying the dorsal part of the optic vesicle (arrows). (F) At stage 8, Mitf expression is not observed in the optic primordium (arrow). (G) Mitf expression is strongest in the distal part of the optic vesicle at stage 9 (arrows). The arrowheads indicate neural crest cells dorsally. (H) At stage 10, Mitf expression is observed in the presumptive RPE (dorsal optic vesicle) and in the distal part (arrows). See A for the location of this section; see also R,S,T. (I) Bmp7 expression is observed in the ectoderm overlying the optic primordium at stage 8 (arrows), and diffuse expression is detected in the neural folds (arrowheads). (J) Parallel section of the embryo shown in G. At stage 9, strong Bmp7 expression is observed in the overlying ectoderm (arrows). Bmp7 transcripts are also detected in the dorsal ectoderm that covers the neural crest cells (arrowheads). (K) Bmp7 expression in the ectoderm overlying the distal region of the optic vesicle at stage 10 (arrows). Transcripts are still observed in the ectoderm overlying the mesenchyme (arrowhead). (L) At stage 8, Bmp4 transcripts are detected in the overlying ectoderm (arrow) and in the neural folds (arrowheads). (M) Strong Bmp4 expression is detected in the ectoderm overlying the distal portion of the optic vesicle at stage 9 (arrows). Weak or no expression is observed in the dorsal-most ectoderm overlying the mesenchymal cells (arrowheads). (N) At stage 10, Bmp4 expression is still strong in the ectoderm overlying the distal portion of the optic vesicle (arrows), whereas weak expression is observed in the ectoderm overlying the surrounding mesenchyme (arrowhead). Note that Bmp4 expression appears to be stronger in the ectoderm overlying the dorsal portion of the optic vesicle. (O) At stage 8, <t>Bmp5</t> expression is strong in the dorsal midline, the neural folds (arrowheads). Transcripts appear to be absent from the overlying ectoderm. (P) Bmp5 expression weakens in the dorsal midline at stage 9 (arrowhead). (Q) No Bmp5 transcripts are detected in the neuroepithelium of the chick optic vesicle and surrounding tissues (arrow) at stage 10. (R) Nasal region of the optic vesicle at stage 10. Mitf expression in the distal and dorsal part of the optic vesicle (arrowheads). (S) Higher magnification of the Mitf expression pattern in the more-temporal region of the optic vesicle shown in H. Mitf expression is detected in both the dorsal and distal region of the optic vesicle (arrowheads), although expression weakens ventrally (arrow). (T) In the most-temporal region of the optic vesicle, Mitf expression is downregulated in the disto-ventral region (arrow).
Recombinant Mouse Bmp5, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmp5/Recombinant+Mouse+BMP-5+Protein/pm17728349-78-5-15
Average 92 stars, based on 1 article reviews
recombinant mouse bmp5 - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier

91
Cusabio human mature bmp5
Fig. 2. Comparison of the Sox10, Mitf and Bmp expression patterns during the initial stages of chick eye development. (A) Schematic illustrating the location of the section in H, showing the nasal part of the optic vesicle at stage 10/11. (B) Bmp4 expression in the surface ectoderm overlying the optic vesicle following whole-mount in situ hybridisation (13 somites). The optic primordium is shown at stage 8 (6 somites; C,F,I,L,O), at stage 9 (7-9 somites; D,G,J,M,P) and stage 10 (10-12 somites; E,H,K,N,Q). (C) At stage 8, Sox10-positive neural crest cells are observed in the dorsal neural folds of the prosencephalon (arrows). (D) Sox10-expressing neural crest cells are detected in the dorsal-most region of the prosencephalon (arrows) and no transcripts are detected distally. (E) Sox10 expression is detected in neural crest cells overlying the dorsal part of the optic vesicle (arrows). (F) At stage 8, Mitf expression is not observed in the optic primordium (arrow). (G) Mitf expression is strongest in the distal part of the optic vesicle at stage 9 (arrows). The arrowheads indicate neural crest cells dorsally. (H) At stage 10, Mitf expression is observed in the presumptive RPE (dorsal optic vesicle) and in the distal part (arrows). See A for the location of this section; see also R,S,T. (I) Bmp7 expression is observed in the ectoderm overlying the optic primordium at stage 8 (arrows), and diffuse expression is detected in the neural folds (arrowheads). (J) Parallel section of the embryo shown in G. At stage 9, strong Bmp7 expression is observed in the overlying ectoderm (arrows). Bmp7 transcripts are also detected in the dorsal ectoderm that covers the neural crest cells (arrowheads). (K) Bmp7 expression in the ectoderm overlying the distal region of the optic vesicle at stage 10 (arrows). Transcripts are still observed in the ectoderm overlying the mesenchyme (arrowhead). (L) At stage 8, Bmp4 transcripts are detected in the overlying ectoderm (arrow) and in the neural folds (arrowheads). (M) Strong Bmp4 expression is detected in the ectoderm overlying the distal portion of the optic vesicle at stage 9 (arrows). Weak or no expression is observed in the dorsal-most ectoderm overlying the mesenchymal cells (arrowheads). (N) At stage 10, Bmp4 expression is still strong in the ectoderm overlying the distal portion of the optic vesicle (arrows), whereas weak expression is observed in the ectoderm overlying the surrounding mesenchyme (arrowhead). Note that Bmp4 expression appears to be stronger in the ectoderm overlying the dorsal portion of the optic vesicle. (O) At stage 8, <t>Bmp5</t> expression is strong in the dorsal midline, the neural folds (arrowheads). Transcripts appear to be absent from the overlying ectoderm. (P) Bmp5 expression weakens in the dorsal midline at stage 9 (arrowhead). (Q) No Bmp5 transcripts are detected in the neuroepithelium of the chick optic vesicle and surrounding tissues (arrow) at stage 10. (R) Nasal region of the optic vesicle at stage 10. Mitf expression in the distal and dorsal part of the optic vesicle (arrowheads). (S) Higher magnification of the Mitf expression pattern in the more-temporal region of the optic vesicle shown in H. Mitf expression is detected in both the dorsal and distal region of the optic vesicle (arrowheads), although expression weakens ventrally (arrow). (T) In the most-temporal region of the optic vesicle, Mitf expression is downregulated in the disto-ventral region (arrow).
Human Mature Bmp5, supplied by Cusabio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmp5/BMP5/pm37666445-92-25-49
Average 91 stars, based on 1 article reviews
human mature bmp5 - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier

90
R&D Systems recombinant human bmp5
(A) Heatmap of genes with significant differential expression in BPH versus normal prostate. Samples are clustered (see color key) and genes ordered by SAM score (t statistic value). (B) Volcano plot (Q value vs. log2 fold change) annotated with topmost genes differentially expressed in BPH. (C) Technical validation of RNA-Seq results by qRT-PCR, confirming elevated expression of <t>BMP5</t> and CXCL13 in BPH. Five BPH-normal pairs assayed once with technical quadruplicates. Graphed are mean (±1 SD) relative expression levels, normalized to GAPDH and compared against a reference sample (normal prostate sample 8791). Each data point represents 1 of up to 16 pairwise ratios (calculated from the quadruplicate test and reference values). Below, heatmap depiction of corresponding RNA-Seq (median-centered log2 reads per kilobase million) values.
Recombinant Human Bmp5, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmp5/Recombinant+Human+BMP-5+(CHO-expressed)+Protein%2C+CF/pmc06629137-363-12-15
Average 90 stars, based on 1 article reviews
recombinant human bmp5 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
R&D Systems af615
(A) Heatmap of genes with significant differential expression in BPH versus normal prostate. Samples are clustered (see color key) and genes ordered by SAM score (t statistic value). (B) Volcano plot (Q value vs. log2 fold change) annotated with topmost genes differentially expressed in BPH. (C) Technical validation of RNA-Seq results by qRT-PCR, confirming elevated expression of <t>BMP5</t> and CXCL13 in BPH. Five BPH-normal pairs assayed once with technical quadruplicates. Graphed are mean (±1 SD) relative expression levels, normalized to GAPDH and compared against a reference sample (normal prostate sample 8791). Each data point represents 1 of up to 16 pairwise ratios (calculated from the quadruplicate test and reference values). Below, heatmap depiction of corresponding RNA-Seq (median-centered log2 reads per kilobase million) values.
Af615, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmp5/Human+BMP-5+Antibody/pm28350991-199-99-104
Average 90 stars, based on 1 article reviews
af615 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

94
MedChemExpress culture medium
(A) Heatmap of genes with significant differential expression in BPH versus normal prostate. Samples are clustered (see color key) and genes ordered by SAM score (t statistic value). (B) Volcano plot (Q value vs. log2 fold change) annotated with topmost genes differentially expressed in BPH. (C) Technical validation of RNA-Seq results by qRT-PCR, confirming elevated expression of <t>BMP5</t> and CXCL13 in BPH. Five BPH-normal pairs assayed once with technical quadruplicates. Graphed are mean (±1 SD) relative expression levels, normalized to GAPDH and compared against a reference sample (normal prostate sample 8791). Each data point represents 1 of up to 16 pairwise ratios (calculated from the quadruplicate test and reference values). Below, heatmap depiction of corresponding RNA-Seq (median-centered log2 reads per kilobase million) values.
Culture Medium, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmp5/BMP-5%2C+Human/pm41760598-238-26-21
Average 94 stars, based on 1 article reviews
culture medium - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

Image Search Results


GLDN regulates BMP5/P-SMAD1/5/9 signaling in GLDN + OSCs. a uMAP representation of BMP5 . b IF co-staining of GLDN (green) and BMP5 (red) in sagittal sections of human developing DP tissues at an early root development stage (with root development not exceeding one-third of its final length), with DAPI (blue) indicating cell nuclei. Gel images ( c ) and grayscale value analysis of BMP5 ( d ) and P-SMAD1/5/9 ( e ) expression in GLDN-negative cells and GLDN + OSCs. n = 3. f ELISA analysis of BMP5 expression levels in CM from GLDN - DPSCs and GLDN + OSCs. n = 4. g – i Effects of GLDN silencing on BMP5 and P-SMAD1/5/9 expression in GLDN + OSCs. n = 3. j Expression of BMP5 in GLDN + OSCs-derived CM after GLDN silencing was assessed by ELISA. n = 4. k , l Effects of CM from GLDN + OSCs with GLDN silencing on P-SMAD1/5/9 expression in HUVEC cells. n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.000 1; ns no significance

Journal: International Journal of Oral Science

Article Title: Identification of GLDN + odontogenic stem cells as crucial for human tooth development and regeneration

doi: 10.1038/s41368-025-00419-y

Figure Lengend Snippet: GLDN regulates BMP5/P-SMAD1/5/9 signaling in GLDN + OSCs. a uMAP representation of BMP5 . b IF co-staining of GLDN (green) and BMP5 (red) in sagittal sections of human developing DP tissues at an early root development stage (with root development not exceeding one-third of its final length), with DAPI (blue) indicating cell nuclei. Gel images ( c ) and grayscale value analysis of BMP5 ( d ) and P-SMAD1/5/9 ( e ) expression in GLDN-negative cells and GLDN + OSCs. n = 3. f ELISA analysis of BMP5 expression levels in CM from GLDN - DPSCs and GLDN + OSCs. n = 4. g – i Effects of GLDN silencing on BMP5 and P-SMAD1/5/9 expression in GLDN + OSCs. n = 3. j Expression of BMP5 in GLDN + OSCs-derived CM after GLDN silencing was assessed by ELISA. n = 4. k , l Effects of CM from GLDN + OSCs with GLDN silencing on P-SMAD1/5/9 expression in HUVEC cells. n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.000 1; ns no significance

Article Snippet: In the cell proliferation, migration, tube formation, and osteogenic induction assays, human BMP5 recombinant protein (HEK293, hFc) (#HY- P75472 ; MCE) was added to the culture medium or osteogenic induction medium at the onset of the experiment and maintained throughout.

Techniques: Staining, Expressing, Enzyme-linked Immunosorbent Assay, Derivative Assay

The role of BMP5/P-SMAD1/5/9 signaling in regulating the mineralization potential of GLDN + OSCs. Validation of the silencing efficiency of BMP5 ( a , b ) and its effects on the expression of P-SMAD1/5/9 ( a , c ) in GLDN + OSCs. n = 3. Alkaline phosphatase (ALP) ( d , e ) ( n = 6) and Alizarin red staining ( f , g ) ( n = 6) were utilized to assess the effects of BMP5 silencing on the mineralization potential of GLDN + OSCs. h , i Effects of BMP5 silencing on the expression of DSPP, DMP1, and RUNX2 in GLDN + OSCs during osteogenic induction on days 3, 7, and 14 are reported. n = 3. ALP staining ( j , k ; n = 6) and Alizarin Red staining ( l , m ; n = 6) to assess the effect of different concentrations of BMP5 on the mineralization potential of GLDN − DPSCs. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.000 1; ns no significance

Journal: International Journal of Oral Science

Article Title: Identification of GLDN + odontogenic stem cells as crucial for human tooth development and regeneration

doi: 10.1038/s41368-025-00419-y

Figure Lengend Snippet: The role of BMP5/P-SMAD1/5/9 signaling in regulating the mineralization potential of GLDN + OSCs. Validation of the silencing efficiency of BMP5 ( a , b ) and its effects on the expression of P-SMAD1/5/9 ( a , c ) in GLDN + OSCs. n = 3. Alkaline phosphatase (ALP) ( d , e ) ( n = 6) and Alizarin red staining ( f , g ) ( n = 6) were utilized to assess the effects of BMP5 silencing on the mineralization potential of GLDN + OSCs. h , i Effects of BMP5 silencing on the expression of DSPP, DMP1, and RUNX2 in GLDN + OSCs during osteogenic induction on days 3, 7, and 14 are reported. n = 3. ALP staining ( j , k ; n = 6) and Alizarin Red staining ( l , m ; n = 6) to assess the effect of different concentrations of BMP5 on the mineralization potential of GLDN − DPSCs. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.000 1; ns no significance

Article Snippet: In the cell proliferation, migration, tube formation, and osteogenic induction assays, human BMP5 recombinant protein (HEK293, hFc) (#HY- P75472 ; MCE) was added to the culture medium or osteogenic induction medium at the onset of the experiment and maintained throughout.

Techniques: Biomarker Discovery, Expressing, Staining

Effects of exogenous BMP5/P-SMAD1/5/9 signaling on the tube formation capacities of HUVECs. a Expression of BMP5 in GLDN + OSCs-derived CM after BMP5 silencing. n = 4. b , c Expression of P-SMAD1/5/9 in HUVECs cultured with GLDN + OSCs CM after BMP5 silencing. n = 3. d , f – h The impact of BMP5 silencing in GLDN + OSCs CM on HUVEC tube formation. n = 5. e , i The effects of varying concentrations of BMP5 recombinant protein on the expression of P-SMAD1/5/9 in HUVEC are presented. n = 3. j – m The effect of different concentrations of BMP5 on tube formation in HUVEC. n = 5. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.000 1; ns no significance

Journal: International Journal of Oral Science

Article Title: Identification of GLDN + odontogenic stem cells as crucial for human tooth development and regeneration

doi: 10.1038/s41368-025-00419-y

Figure Lengend Snippet: Effects of exogenous BMP5/P-SMAD1/5/9 signaling on the tube formation capacities of HUVECs. a Expression of BMP5 in GLDN + OSCs-derived CM after BMP5 silencing. n = 4. b , c Expression of P-SMAD1/5/9 in HUVECs cultured with GLDN + OSCs CM after BMP5 silencing. n = 3. d , f – h The impact of BMP5 silencing in GLDN + OSCs CM on HUVEC tube formation. n = 5. e , i The effects of varying concentrations of BMP5 recombinant protein on the expression of P-SMAD1/5/9 in HUVEC are presented. n = 3. j – m The effect of different concentrations of BMP5 on tube formation in HUVEC. n = 5. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.000 1; ns no significance

Article Snippet: In the cell proliferation, migration, tube formation, and osteogenic induction assays, human BMP5 recombinant protein (HEK293, hFc) (#HY- P75472 ; MCE) was added to the culture medium or osteogenic induction medium at the onset of the experiment and maintained throughout.

Techniques: Expressing, Derivative Assay, Cell Culture, Recombinant

G9a knockdown may lead to increase in BMP5 expression. ( A ) Regulatory factors suppressing tumor aggressiveness were identified by using microarray analysis. ( B ) Expression levels for each gene were compared (ratios between gene expression levels of non-silencing control). In two G9a knockdown cells (shG9a #1 and shG9a #2), expression levels for each gene were compared to those of non-silencing control. Then the most upregulated and downregulated genes were screened. ( C ) G9a knockdown cells showed increase in BMP5 expression. ( D ) Reduced G9a occupancy was found at the BMP5 promoter region. G9a knockdown cells also showed decreased H3K9me2 occupancy at the promoter region of BMP5. p values were calculated using ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: International Journal of Molecular Sciences

Article Title: G9a Knockdown Suppresses Cancer Aggressiveness by Facilitating Smad Protein Phosphorylation through Increasing BMP5 Expression in Luminal A Type Breast Cancer

doi: 10.3390/ijms23020589

Figure Lengend Snippet: G9a knockdown may lead to increase in BMP5 expression. ( A ) Regulatory factors suppressing tumor aggressiveness were identified by using microarray analysis. ( B ) Expression levels for each gene were compared (ratios between gene expression levels of non-silencing control). In two G9a knockdown cells (shG9a #1 and shG9a #2), expression levels for each gene were compared to those of non-silencing control. Then the most upregulated and downregulated genes were screened. ( C ) G9a knockdown cells showed increase in BMP5 expression. ( D ) Reduced G9a occupancy was found at the BMP5 promoter region. G9a knockdown cells also showed decreased H3K9me2 occupancy at the promoter region of BMP5. p values were calculated using ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: Western blot analysis was performed with antibodies specific for the following proteins: G9a (#229455, Abcam, Cambridge, MA, USA), E-cadherin (#3195S, Cell Signaling, Boston, MA, USA), β-catenin (#8480P, Cell Signaling, Boston, MA, USA), ZO-1 (#5406P, Cell signaling, Boston, MA, USA), PARP (#9542S, Cell signaling, Boston, MA, USA), Caspase-7 (#9492S, Cell signaling, Boston, MA, USA), BMP5 (#13253-1-AP, Proteintech, Chicago, IL, USA), p -Smad1/5/9 (#13820T, Cell Signaling, Boston, MA, USA), p -Smad1/5 (#9516T, Cell Signaling, Boston, MA, USA), Smad1 (#6944T, Cell Signaling, Boston, MA, USA) and β-actin.

Techniques: Knockdown, Expressing, Microarray, Gene Expression, Control

BMP5 contributes to reduce migration and invasion abilities of tumor cells. ( A ) Low BMP5 expression is associated with poor survival outcomes of breast cancer patients. ( B ) Patients with stage 3 disease showed higher BMP5 levels than those of stage 2 patients. ( C , D ) Migration/invasion abilities were decreased by treatment of recombinant BMP5; however, the capabilities were enhanced following BMP5 downregulation. p values were calculated using ANOVA. * p < 0.05, ** p < 0.01, **** p < 0.0001.

Journal: International Journal of Molecular Sciences

Article Title: G9a Knockdown Suppresses Cancer Aggressiveness by Facilitating Smad Protein Phosphorylation through Increasing BMP5 Expression in Luminal A Type Breast Cancer

doi: 10.3390/ijms23020589

Figure Lengend Snippet: BMP5 contributes to reduce migration and invasion abilities of tumor cells. ( A ) Low BMP5 expression is associated with poor survival outcomes of breast cancer patients. ( B ) Patients with stage 3 disease showed higher BMP5 levels than those of stage 2 patients. ( C , D ) Migration/invasion abilities were decreased by treatment of recombinant BMP5; however, the capabilities were enhanced following BMP5 downregulation. p values were calculated using ANOVA. * p < 0.05, ** p < 0.01, **** p < 0.0001.

Article Snippet: Western blot analysis was performed with antibodies specific for the following proteins: G9a (#229455, Abcam, Cambridge, MA, USA), E-cadherin (#3195S, Cell Signaling, Boston, MA, USA), β-catenin (#8480P, Cell Signaling, Boston, MA, USA), ZO-1 (#5406P, Cell signaling, Boston, MA, USA), PARP (#9542S, Cell signaling, Boston, MA, USA), Caspase-7 (#9492S, Cell signaling, Boston, MA, USA), BMP5 (#13253-1-AP, Proteintech, Chicago, IL, USA), p -Smad1/5/9 (#13820T, Cell Signaling, Boston, MA, USA), p -Smad1/5 (#9516T, Cell Signaling, Boston, MA, USA), Smad1 (#6944T, Cell Signaling, Boston, MA, USA) and β-actin.

Techniques: Migration, Expressing, Recombinant

G9a knockdown facilitates Smad protein phosphorylation via BMP5 activation. ( A , B ) G9a-knockdown-induced increase in BMP5 expression had no effect on the total level of either Smad1 or Smad5. G9a knockdown increased phosphorylation of Smad1/5/9. ( C ) ICC demonstrated that nuclear translocation of pSmad1/5/9 was increased in G9a-depleted MCF7 cells. ( D ) Similar tendency was found after treatment of recombinant BMP5. p values were calculated using ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns = not significant.

Journal: International Journal of Molecular Sciences

Article Title: G9a Knockdown Suppresses Cancer Aggressiveness by Facilitating Smad Protein Phosphorylation through Increasing BMP5 Expression in Luminal A Type Breast Cancer

doi: 10.3390/ijms23020589

Figure Lengend Snippet: G9a knockdown facilitates Smad protein phosphorylation via BMP5 activation. ( A , B ) G9a-knockdown-induced increase in BMP5 expression had no effect on the total level of either Smad1 or Smad5. G9a knockdown increased phosphorylation of Smad1/5/9. ( C ) ICC demonstrated that nuclear translocation of pSmad1/5/9 was increased in G9a-depleted MCF7 cells. ( D ) Similar tendency was found after treatment of recombinant BMP5. p values were calculated using ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns = not significant.

Article Snippet: Western blot analysis was performed with antibodies specific for the following proteins: G9a (#229455, Abcam, Cambridge, MA, USA), E-cadherin (#3195S, Cell Signaling, Boston, MA, USA), β-catenin (#8480P, Cell Signaling, Boston, MA, USA), ZO-1 (#5406P, Cell signaling, Boston, MA, USA), PARP (#9542S, Cell signaling, Boston, MA, USA), Caspase-7 (#9492S, Cell signaling, Boston, MA, USA), BMP5 (#13253-1-AP, Proteintech, Chicago, IL, USA), p -Smad1/5/9 (#13820T, Cell Signaling, Boston, MA, USA), p -Smad1/5 (#9516T, Cell Signaling, Boston, MA, USA), Smad1 (#6944T, Cell Signaling, Boston, MA, USA) and β-actin.

Techniques: Knockdown, Phospho-proteomics, Activation Assay, Expressing, Translocation Assay, Recombinant

Fig. 9. Megalin mediates binding and cellular catabolism of BMP4. (A) Surface plasmon resonance (SPR) analysis of binding of 0.5 µmol/l BMP4 but not of 0.5 µmol/l BMP5 or WNT1- conditioned medium to purified megalin immobilized on the sensor chip surface (see Materials and methods for details). As a positive control, binding of 1 µmol/l receptor-associated protein (RAP) to megalin was tested. (B) Megalin-expressing BN16 cells mediate uptake and lysosomal degradation of 125I-BMP4. Degradation of BMP4 can be blocked by chloroquine (200 µmol/l) or the receptor-antagonist RAP (100 µg/ml).

Journal: Development (Cambridge, England)

Article Title: LRP2/megalin is required for patterning of the ventral telencephalon.

doi: 10.1242/dev.01580

Figure Lengend Snippet: Fig. 9. Megalin mediates binding and cellular catabolism of BMP4. (A) Surface plasmon resonance (SPR) analysis of binding of 0.5 µmol/l BMP4 but not of 0.5 µmol/l BMP5 or WNT1- conditioned medium to purified megalin immobilized on the sensor chip surface (see Materials and methods for details). As a positive control, binding of 1 µmol/l receptor-associated protein (RAP) to megalin was tested. (B) Megalin-expressing BN16 cells mediate uptake and lysosomal degradation of 125I-BMP4. Degradation of BMP4 can be blocked by chloroquine (200 µmol/l) or the receptor-antagonist RAP (100 µg/ml).

Article Snippet: BIAcore analysis and cell culture experiments Carrier-free preparations of recombinant human BMP4 and BMP5 were purchased from Research and Development (www.RnDSystems.com).

Techniques: Binding Assay, SPR Assay, Positive Control, Expressing

Fig. 2. Comparison of the Sox10, Mitf and Bmp expression patterns during the initial stages of chick eye development. (A) Schematic illustrating the location of the section in H, showing the nasal part of the optic vesicle at stage 10/11. (B) Bmp4 expression in the surface ectoderm overlying the optic vesicle following whole-mount in situ hybridisation (13 somites). The optic primordium is shown at stage 8 (6 somites; C,F,I,L,O), at stage 9 (7-9 somites; D,G,J,M,P) and stage 10 (10-12 somites; E,H,K,N,Q). (C) At stage 8, Sox10-positive neural crest cells are observed in the dorsal neural folds of the prosencephalon (arrows). (D) Sox10-expressing neural crest cells are detected in the dorsal-most region of the prosencephalon (arrows) and no transcripts are detected distally. (E) Sox10 expression is detected in neural crest cells overlying the dorsal part of the optic vesicle (arrows). (F) At stage 8, Mitf expression is not observed in the optic primordium (arrow). (G) Mitf expression is strongest in the distal part of the optic vesicle at stage 9 (arrows). The arrowheads indicate neural crest cells dorsally. (H) At stage 10, Mitf expression is observed in the presumptive RPE (dorsal optic vesicle) and in the distal part (arrows). See A for the location of this section; see also R,S,T. (I) Bmp7 expression is observed in the ectoderm overlying the optic primordium at stage 8 (arrows), and diffuse expression is detected in the neural folds (arrowheads). (J) Parallel section of the embryo shown in G. At stage 9, strong Bmp7 expression is observed in the overlying ectoderm (arrows). Bmp7 transcripts are also detected in the dorsal ectoderm that covers the neural crest cells (arrowheads). (K) Bmp7 expression in the ectoderm overlying the distal region of the optic vesicle at stage 10 (arrows). Transcripts are still observed in the ectoderm overlying the mesenchyme (arrowhead). (L) At stage 8, Bmp4 transcripts are detected in the overlying ectoderm (arrow) and in the neural folds (arrowheads). (M) Strong Bmp4 expression is detected in the ectoderm overlying the distal portion of the optic vesicle at stage 9 (arrows). Weak or no expression is observed in the dorsal-most ectoderm overlying the mesenchymal cells (arrowheads). (N) At stage 10, Bmp4 expression is still strong in the ectoderm overlying the distal portion of the optic vesicle (arrows), whereas weak expression is observed in the ectoderm overlying the surrounding mesenchyme (arrowhead). Note that Bmp4 expression appears to be stronger in the ectoderm overlying the dorsal portion of the optic vesicle. (O) At stage 8, Bmp5 expression is strong in the dorsal midline, the neural folds (arrowheads). Transcripts appear to be absent from the overlying ectoderm. (P) Bmp5 expression weakens in the dorsal midline at stage 9 (arrowhead). (Q) No Bmp5 transcripts are detected in the neuroepithelium of the chick optic vesicle and surrounding tissues (arrow) at stage 10. (R) Nasal region of the optic vesicle at stage 10. Mitf expression in the distal and dorsal part of the optic vesicle (arrowheads). (S) Higher magnification of the Mitf expression pattern in the more-temporal region of the optic vesicle shown in H. Mitf expression is detected in both the dorsal and distal region of the optic vesicle (arrowheads), although expression weakens ventrally (arrow). (T) In the most-temporal region of the optic vesicle, Mitf expression is downregulated in the disto-ventral region (arrow).

Journal: Development (Cambridge, England)

Article Title: Bone morphogenetic proteins specify the retinal pigment epithelium in the chick embryo.

doi: 10.1242/dev.02884

Figure Lengend Snippet: Fig. 2. Comparison of the Sox10, Mitf and Bmp expression patterns during the initial stages of chick eye development. (A) Schematic illustrating the location of the section in H, showing the nasal part of the optic vesicle at stage 10/11. (B) Bmp4 expression in the surface ectoderm overlying the optic vesicle following whole-mount in situ hybridisation (13 somites). The optic primordium is shown at stage 8 (6 somites; C,F,I,L,O), at stage 9 (7-9 somites; D,G,J,M,P) and stage 10 (10-12 somites; E,H,K,N,Q). (C) At stage 8, Sox10-positive neural crest cells are observed in the dorsal neural folds of the prosencephalon (arrows). (D) Sox10-expressing neural crest cells are detected in the dorsal-most region of the prosencephalon (arrows) and no transcripts are detected distally. (E) Sox10 expression is detected in neural crest cells overlying the dorsal part of the optic vesicle (arrows). (F) At stage 8, Mitf expression is not observed in the optic primordium (arrow). (G) Mitf expression is strongest in the distal part of the optic vesicle at stage 9 (arrows). The arrowheads indicate neural crest cells dorsally. (H) At stage 10, Mitf expression is observed in the presumptive RPE (dorsal optic vesicle) and in the distal part (arrows). See A for the location of this section; see also R,S,T. (I) Bmp7 expression is observed in the ectoderm overlying the optic primordium at stage 8 (arrows), and diffuse expression is detected in the neural folds (arrowheads). (J) Parallel section of the embryo shown in G. At stage 9, strong Bmp7 expression is observed in the overlying ectoderm (arrows). Bmp7 transcripts are also detected in the dorsal ectoderm that covers the neural crest cells (arrowheads). (K) Bmp7 expression in the ectoderm overlying the distal region of the optic vesicle at stage 10 (arrows). Transcripts are still observed in the ectoderm overlying the mesenchyme (arrowhead). (L) At stage 8, Bmp4 transcripts are detected in the overlying ectoderm (arrow) and in the neural folds (arrowheads). (M) Strong Bmp4 expression is detected in the ectoderm overlying the distal portion of the optic vesicle at stage 9 (arrows). Weak or no expression is observed in the dorsal-most ectoderm overlying the mesenchymal cells (arrowheads). (N) At stage 10, Bmp4 expression is still strong in the ectoderm overlying the distal portion of the optic vesicle (arrows), whereas weak expression is observed in the ectoderm overlying the surrounding mesenchyme (arrowhead). Note that Bmp4 expression appears to be stronger in the ectoderm overlying the dorsal portion of the optic vesicle. (O) At stage 8, Bmp5 expression is strong in the dorsal midline, the neural folds (arrowheads). Transcripts appear to be absent from the overlying ectoderm. (P) Bmp5 expression weakens in the dorsal midline at stage 9 (arrowhead). (Q) No Bmp5 transcripts are detected in the neuroepithelium of the chick optic vesicle and surrounding tissues (arrow) at stage 10. (R) Nasal region of the optic vesicle at stage 10. Mitf expression in the distal and dorsal part of the optic vesicle (arrowheads). (S) Higher magnification of the Mitf expression pattern in the more-temporal region of the optic vesicle shown in H. Mitf expression is detected in both the dorsal and distal region of the optic vesicle (arrowheads), although expression weakens ventrally (arrow). (T) In the most-temporal region of the optic vesicle, Mitf expression is downregulated in the disto-ventral region (arrow).

Article Snippet: A 2 l drop of recombinant mouse BMP5 or BMP4 (0.7 mg/ml or 1 mg/ml; R&D Systems) was placed in a Petri dish and about eight drops (10 l each) of distilled water were placed around it to keep it from evaporating.

Techniques: Comparison, Expressing, In Situ, Hybridization

Fig. 3. Effects of BMP and noggin application on the Wnt2b expression pattern during early stages of eye development. (A) Schematic of a stage 10/11 chick embryo showing the implantation site of the BMP5-soaked bead in E. (B) At stage 13, Wnt2b transcripts are restricted to the presumptive RPE (arrow). The arrowhead indicates Wnt2b expression in the ectoderm. (C) Wnt2b transcripts are detected in the RPE (arrows) and surface ectoderm (arrowhead) on the contralateral side of the BMP5-treated eye shown in E. (D) Wnt2b expression in the contralateral, untreated eye following implantation of noggin-expressing cells. Wnt2b transcripts are restricted to the RPE (arrowhead) and no transcripts are detected within the NR. The arrow shows Wnt2b expression within the ectoderm and anterior lens. (E) Following BMP5 application (asterisk), Wnt2b expression is also detected in the distal region of the optic vesicle, the presumptive NR (arrows). The arrowhead indicates Wnt2b expression in the ectoderm. (F) Parallel section of the noggin-treated eye shown in Fig. 5B,D. Wnt2b expression is downregulated in the entire outer optic cup (arrowheads). In the surface ectoderm (arrow) and anterior lens, Wnt2b expression is still detected.

Journal: Development (Cambridge, England)

Article Title: Bone morphogenetic proteins specify the retinal pigment epithelium in the chick embryo.

doi: 10.1242/dev.02884

Figure Lengend Snippet: Fig. 3. Effects of BMP and noggin application on the Wnt2b expression pattern during early stages of eye development. (A) Schematic of a stage 10/11 chick embryo showing the implantation site of the BMP5-soaked bead in E. (B) At stage 13, Wnt2b transcripts are restricted to the presumptive RPE (arrow). The arrowhead indicates Wnt2b expression in the ectoderm. (C) Wnt2b transcripts are detected in the RPE (arrows) and surface ectoderm (arrowhead) on the contralateral side of the BMP5-treated eye shown in E. (D) Wnt2b expression in the contralateral, untreated eye following implantation of noggin-expressing cells. Wnt2b transcripts are restricted to the RPE (arrowhead) and no transcripts are detected within the NR. The arrow shows Wnt2b expression within the ectoderm and anterior lens. (E) Following BMP5 application (asterisk), Wnt2b expression is also detected in the distal region of the optic vesicle, the presumptive NR (arrows). The arrowhead indicates Wnt2b expression in the ectoderm. (F) Parallel section of the noggin-treated eye shown in Fig. 5B,D. Wnt2b expression is downregulated in the entire outer optic cup (arrowheads). In the surface ectoderm (arrow) and anterior lens, Wnt2b expression is still detected.

Article Snippet: A 2 l drop of recombinant mouse BMP5 or BMP4 (0.7 mg/ml or 1 mg/ml; R&D Systems) was placed in a Petri dish and about eight drops (10 l each) of distilled water were placed around it to keep it from evaporating.

Techniques: Expressing

Fig. 4. Effects of BMP5 application on the distribution of genes expressed within the NR and RPE at optic cup stages. (A) Schematic illustrating the location of the BMP5-soaked bead following implantation at stage 10/11 as shown in E-I; B-D are PBS-soaked bead controls (B) In control embryos, Mitf expression is weakly detected in the RPE at stage 15 (arrowheads). (C) The RPE-specific marker MMP115 is restricted to the RPE at this stage (arrowheads). (D) Strong Rx expression is detected in the NR at this stage (arrowhead). (E) Following implantation of a BMP5-soaked bead (asterisk), optic cup formation is not observed and Mitf expression is detected in the distal optic vesicle (arrowheads). (F) Parallel section of the embryo shown in E and G. MMP115 expression is induced in the presumptive NR (arrowhead) and the optic stalk region following BMP5 exposure. (G) Implantation of a BMP5-soaked bead (asterisk) leads to downregulation of Rx expression in the presumptive NR. (H) BMP5 application downregulates Chx10 expression in the distal optic vesicle/cup, the presumptive NR (right, arrowheads). By contrast, Chx10 expression is strongly observed within the presumptive NR of the contralateral eye (left, arrow). (I) Parallel section of the embryo shown in H. MMP115 expression is induced by BMP5 in the presumptive NR (arrowheads), whereas in the contralateral, unoperated eye, MMP115 transcripts are absent from the NR (left, arrow). L, Lens.

Journal: Development (Cambridge, England)

Article Title: Bone morphogenetic proteins specify the retinal pigment epithelium in the chick embryo.

doi: 10.1242/dev.02884

Figure Lengend Snippet: Fig. 4. Effects of BMP5 application on the distribution of genes expressed within the NR and RPE at optic cup stages. (A) Schematic illustrating the location of the BMP5-soaked bead following implantation at stage 10/11 as shown in E-I; B-D are PBS-soaked bead controls (B) In control embryos, Mitf expression is weakly detected in the RPE at stage 15 (arrowheads). (C) The RPE-specific marker MMP115 is restricted to the RPE at this stage (arrowheads). (D) Strong Rx expression is detected in the NR at this stage (arrowhead). (E) Following implantation of a BMP5-soaked bead (asterisk), optic cup formation is not observed and Mitf expression is detected in the distal optic vesicle (arrowheads). (F) Parallel section of the embryo shown in E and G. MMP115 expression is induced in the presumptive NR (arrowhead) and the optic stalk region following BMP5 exposure. (G) Implantation of a BMP5-soaked bead (asterisk) leads to downregulation of Rx expression in the presumptive NR. (H) BMP5 application downregulates Chx10 expression in the distal optic vesicle/cup, the presumptive NR (right, arrowheads). By contrast, Chx10 expression is strongly observed within the presumptive NR of the contralateral eye (left, arrow). (I) Parallel section of the embryo shown in H. MMP115 expression is induced by BMP5 in the presumptive NR (arrowheads), whereas in the contralateral, unoperated eye, MMP115 transcripts are absent from the NR (left, arrow). L, Lens.

Article Snippet: A 2 l drop of recombinant mouse BMP5 or BMP4 (0.7 mg/ml or 1 mg/ml; R&D Systems) was placed in a Petri dish and about eight drops (10 l each) of distilled water were placed around it to keep it from evaporating.

Techniques: Control, Expressing, Marker

(A) Heatmap of genes with significant differential expression in BPH versus normal prostate. Samples are clustered (see color key) and genes ordered by SAM score (t statistic value). (B) Volcano plot (Q value vs. log2 fold change) annotated with topmost genes differentially expressed in BPH. (C) Technical validation of RNA-Seq results by qRT-PCR, confirming elevated expression of BMP5 and CXCL13 in BPH. Five BPH-normal pairs assayed once with technical quadruplicates. Graphed are mean (±1 SD) relative expression levels, normalized to GAPDH and compared against a reference sample (normal prostate sample 8791). Each data point represents 1 of up to 16 pairwise ratios (calculated from the quadruplicate test and reference values). Below, heatmap depiction of corresponding RNA-Seq (median-centered log2 reads per kilobase million) values.

Journal: JCI Insight

Article Title: Genomic analysis of benign prostatic hyperplasia implicates cellular relandscaping in disease pathogenesis

doi: 10.1172/jci.insight.129749

Figure Lengend Snippet: (A) Heatmap of genes with significant differential expression in BPH versus normal prostate. Samples are clustered (see color key) and genes ordered by SAM score (t statistic value). (B) Volcano plot (Q value vs. log2 fold change) annotated with topmost genes differentially expressed in BPH. (C) Technical validation of RNA-Seq results by qRT-PCR, confirming elevated expression of BMP5 and CXCL13 in BPH. Five BPH-normal pairs assayed once with technical quadruplicates. Graphed are mean (±1 SD) relative expression levels, normalized to GAPDH and compared against a reference sample (normal prostate sample 8791). Each data point represents 1 of up to 16 pairwise ratios (calculated from the quadruplicate test and reference values). Below, heatmap depiction of corresponding RNA-Seq (median-centered log2 reads per kilobase million) values.

Article Snippet: The 25,000–40,000 cells were plated in 6-well plates in duplicate, and then recombinant human BMP5 (R&D Systems), CXCL13 (R&D Systems), or vehicle control was added daily with media replacement.

Techniques: Quantitative Proteomics, Biomarker Discovery, RNA Sequencing, Quantitative RT-PCR, Expressing

(A) Addition of BMP5 (250 ng/ml) to RWPE-1 prostate epithelial and WPMY-1 myofibroblast cells activates the canonical SMAD pathway, demonstrated by 15- to 20-fold increased phospho-SMAD1/5/9 on Western blot. (B) BMP5 addition (concentrations indicated) to RWPE-1 cells increases cell numbers. Mean (red) and SD (blue) shown. Multiplicity-adjusted P values generated from 1-way ANOVA with post hoc comparison to no BMP5 control (Dunnett’s test); *P < 0.05. Data are representative of 3 independent experiments, each done with 2 samples assayed per concentration. (C) Addition of BMP5 (250 ng/ml) to RWPE-1 cells leads to dispersed cell growth (with fewer cell clusters) and to increased Transwell migration. Mean and SD shown; P value generated from 2-tailed Student’s t test. Data are representative of 2 independent experiments, each done with 3 samples assayed per condition. (D and E) BMP5 addition to RWPE-1 and WPMY-1 cells generates a transcriptional response significantly enriched for BPH (vs. normal prostate) overexpressed genes (left), and with WPMY-1 cells for BPH stromal signature genes (center), but not AR/secretory signature genes (right). Gene set enrichment analysis (GSEA) enrichment score P values are indicated.

Journal: JCI Insight

Article Title: Genomic analysis of benign prostatic hyperplasia implicates cellular relandscaping in disease pathogenesis

doi: 10.1172/jci.insight.129749

Figure Lengend Snippet: (A) Addition of BMP5 (250 ng/ml) to RWPE-1 prostate epithelial and WPMY-1 myofibroblast cells activates the canonical SMAD pathway, demonstrated by 15- to 20-fold increased phospho-SMAD1/5/9 on Western blot. (B) BMP5 addition (concentrations indicated) to RWPE-1 cells increases cell numbers. Mean (red) and SD (blue) shown. Multiplicity-adjusted P values generated from 1-way ANOVA with post hoc comparison to no BMP5 control (Dunnett’s test); *P < 0.05. Data are representative of 3 independent experiments, each done with 2 samples assayed per concentration. (C) Addition of BMP5 (250 ng/ml) to RWPE-1 cells leads to dispersed cell growth (with fewer cell clusters) and to increased Transwell migration. Mean and SD shown; P value generated from 2-tailed Student’s t test. Data are representative of 2 independent experiments, each done with 3 samples assayed per condition. (D and E) BMP5 addition to RWPE-1 and WPMY-1 cells generates a transcriptional response significantly enriched for BPH (vs. normal prostate) overexpressed genes (left), and with WPMY-1 cells for BPH stromal signature genes (center), but not AR/secretory signature genes (right). Gene set enrichment analysis (GSEA) enrichment score P values are indicated.

Article Snippet: The 25,000–40,000 cells were plated in 6-well plates in duplicate, and then recombinant human BMP5 (R&D Systems), CXCL13 (R&D Systems), or vehicle control was added daily with media replacement.

Techniques: Western Blot, Generated, Comparison, Control, Concentration Assay, Migration

(A) Two-dimensional projection (t-SNE plot) of single-cell transcriptomes stratifies prostate tissue cells (dots) into distinct clusters, identifiable by characteristic expression of marker genes, including (B) KRT13 (basal epithelium) (red intensity scales to maximum log2 expression), (C) KLK3 (secretory epithelium), and (D) DCN (fibroblasts). Additional cell type markers are shown in Supplemental Figure 6. (E) Normal prostate tissue cell subset, illustrating expression of (F) CHGA (neuroendocrine cells), (G) BMP5, and (H) CXCL13. (I) BPH tissue cell subset, illustrating expression of (J) CHGA, (K) BMP5, and (L) CXCL13. Note relative depletion in BPH tissue of CHGA-expressing neuroendocrine cells and enrichment of BMP5- or CXCL13-expressing myofibroblasts. Insets magnify select cell clusters. Inset magnification ×1.6.

Journal: JCI Insight

Article Title: Genomic analysis of benign prostatic hyperplasia implicates cellular relandscaping in disease pathogenesis

doi: 10.1172/jci.insight.129749

Figure Lengend Snippet: (A) Two-dimensional projection (t-SNE plot) of single-cell transcriptomes stratifies prostate tissue cells (dots) into distinct clusters, identifiable by characteristic expression of marker genes, including (B) KRT13 (basal epithelium) (red intensity scales to maximum log2 expression), (C) KLK3 (secretory epithelium), and (D) DCN (fibroblasts). Additional cell type markers are shown in Supplemental Figure 6. (E) Normal prostate tissue cell subset, illustrating expression of (F) CHGA (neuroendocrine cells), (G) BMP5, and (H) CXCL13. (I) BPH tissue cell subset, illustrating expression of (J) CHGA, (K) BMP5, and (L) CXCL13. Note relative depletion in BPH tissue of CHGA-expressing neuroendocrine cells and enrichment of BMP5- or CXCL13-expressing myofibroblasts. Insets magnify select cell clusters. Inset magnification ×1.6.

Article Snippet: The 25,000–40,000 cells were plated in 6-well plates in duplicate, and then recombinant human BMP5 (R&D Systems), CXCL13 (R&D Systems), or vehicle control was added daily with media replacement.

Techniques: Expressing, Marker